中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2015年
7期
577-580
,共4页
刘东红%朱丽华%张庆波%曹秀华%石恩富%丁贺田%刘丽
劉東紅%硃麗華%張慶波%曹秀華%石恩富%丁賀田%劉麗
류동홍%주려화%장경파%조수화%석은부%정하전%류려
肿瘤疫苗%食管癌%肿瘤可溶性抗原%超抗原金黄色葡葡球菌肠毒素C型%生物治疗
腫瘤疫苗%食管癌%腫瘤可溶性抗原%超抗原金黃色葡葡毬菌腸毒素C型%生物治療
종류역묘%식관암%종류가용성항원%초항원금황색포포구균장독소C형%생물치료
Tumor vaccine%Eesophagus cancer%Tumor soluble antigen%Superantigen SEC%Tumor biotherapy
目的 探讨食管癌疫苗的抗癌机制及临床应用效果.方法 培养食管癌细胞Eca109,提取其抗原成分和超抗原金黄色葡葡球菌肠毒素C型构建成肿瘤疫苗;分离人外周血单个核细胞(PBMC),与肿瘤疫苗联合作用,进行体外培养增殖,成为效应细胞;流式细胞仪测定效应细胞表型;细胞毒实验检测其杀伤活性.选取早期食管癌术后患者106例,分为观察组53例,应用食管癌疫苗治疗,对照组53例实施常规治疗.观察对比临床应用效果,对两组患者进行3年随访观察其生存率.结果 经肿瘤疫苗刺激的淋巴细胞组增殖活性最强,于72 h达到高峰(A值为0.22);并且上调细胞毒性T细胞(CTLs),CTLs对靶细胞杀伤活性外周血单个核细胞+超抗原金黄色葡萄球菌肠毒素C型+肿瘤可溶性抗原组(97.36±2.11)％显著高于单个核细胞组(79.27±5.57)％,差异有统计学意义(P＜0.01).3年随访发现观察组生存率[男48.28％(14/29)、女45.83％(11/24)]高于对照组[男21.42％(6/28)、女24.00％(6/25)],差异有统计学意义(x2=5.06、x2=6.28,P均＜0.05).结论 食管癌疫苗能诱导效应细胞明显增殖、活化、并产生高效、特异的抗肿瘤效果.临床观察发现其能有效防止食管癌术后患者的复发和肿瘤转移,提高生存率.
目的 探討食管癌疫苗的抗癌機製及臨床應用效果.方法 培養食管癌細胞Eca109,提取其抗原成分和超抗原金黃色葡葡毬菌腸毒素C型構建成腫瘤疫苗;分離人外週血單箇覈細胞(PBMC),與腫瘤疫苗聯閤作用,進行體外培養增殖,成為效應細胞;流式細胞儀測定效應細胞錶型;細胞毒實驗檢測其殺傷活性.選取早期食管癌術後患者106例,分為觀察組53例,應用食管癌疫苗治療,對照組53例實施常規治療.觀察對比臨床應用效果,對兩組患者進行3年隨訪觀察其生存率.結果 經腫瘤疫苗刺激的淋巴細胞組增殖活性最彊,于72 h達到高峰(A值為0.22);併且上調細胞毒性T細胞(CTLs),CTLs對靶細胞殺傷活性外週血單箇覈細胞+超抗原金黃色葡萄毬菌腸毒素C型+腫瘤可溶性抗原組(97.36±2.11)％顯著高于單箇覈細胞組(79.27±5.57)％,差異有統計學意義(P＜0.01).3年隨訪髮現觀察組生存率[男48.28％(14/29)、女45.83％(11/24)]高于對照組[男21.42％(6/28)、女24.00％(6/25)],差異有統計學意義(x2=5.06、x2=6.28,P均＜0.05).結論 食管癌疫苗能誘導效應細胞明顯增殖、活化、併產生高效、特異的抗腫瘤效果.臨床觀察髮現其能有效防止食管癌術後患者的複髮和腫瘤轉移,提高生存率.
목적 탐토식관암역묘적항암궤제급림상응용효과.방법 배양식관암세포Eca109,제취기항원성분화초항원금황색포포구균장독소C형구건성종류역묘;분리인외주혈단개핵세포(PBMC),여종류역묘연합작용,진행체외배양증식,성위효응세포;류식세포의측정효응세포표형;세포독실험검측기살상활성.선취조기식관암술후환자106례,분위관찰조53례,응용식관암역묘치료,대조조53례실시상규치료.관찰대비림상응용효과,대량조환자진행3년수방관찰기생존솔.결과 경종류역묘자격적림파세포조증식활성최강,우72 h체도고봉(A치위0.22);병차상조세포독성T세포(CTLs),CTLs대파세포살상활성외주혈단개핵세포+초항원금황색포도구균장독소C형+종류가용성항원조(97.36±2.11)％현저고우단개핵세포조(79.27±5.57)％,차이유통계학의의(P＜0.01).3년수방발현관찰조생존솔[남48.28％(14/29)、녀45.83％(11/24)]고우대조조[남21.42％(6/28)、녀24.00％(6/25)],차이유통계학의의(x2=5.06、x2=6.28,P균＜0.05).결론 식관암역묘능유도효응세포명현증식、활화、병산생고효、특이적항종류효과.림상관찰발현기능유효방지식관암술후환자적복발화종류전이,제고생존솔.
Objective To explore the anticancer mechanism of esophageal cancer vaccines and clinical effect.Methods Esophagus cancer cells (Eca109) were cultured and the soluble antigen were extracted from the cells.Esophagus cancer vaccine was constructed with the antigen and superantigen SEC.Lymphocytes were isolated from peripheral blood and then stimulated with the vaccine in vitro.Phenotypes of the cells were checked by FCM and killing activity was tested with cytotoxic assays.One hundred and six early esophageal cancer patients were selected after surgery,who were divided into the observation group of 53 cases with esophageal cancer vaccine therapy and 53 cases in the control group with conventional treatment.Then clinical effect was observated and 3 year follow-up survival rate was observed of the of two groups of patients.Results Proliferation of vaccine stimulated lymphocyte group was the strongest,and high peaked at 72 h (A =0.22),and raise CD8+ T cell populations of CTLs.The killing activity of lymphocyte group stimulated by the vaccine against target cells was significantly higher than that of lymphocyte group ((97.36±2.11) ％) vs.(79.27±5.57) ％,F =38.62,P＜0.01).Three years follow up shows that the survival rates of experiment group were 48.27％ (male) and 45.83％ (female) respectively,and control group were 21.43％ (male) and 24.00％ (female),and the difference was significant (x2 =5.06,6.28,P ＜ 0.05).Conclusion The tumor vaccine constructed with esophagus cancer antigen and superantigen SEC can induce PBMC to activate and proliferate into CD8+ CTL with specific cytotoxicity against the cells which the antigen comes from.The vaccine may raise the survival rate of the patients with Esophagus cancer.
